Under the agreement, Anthill will use its Acos high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs.
Joseph Hogan, Jr, CEO of Anthill, said: “We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity.
“We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program.”